Assesses antimicrobial efficacy of tyrosine-rich peptides against multidrug-resistant bacteria, suggesting new treatments.
Multidrug‐resistant (MDR) bacteria pose a significant threat to global public health by undermining conventional antibiotics. Antimicrobial peptides (AMPs), with their membrane‐targeting mechanisms, offer a promising alternative; however, the clinical translation of natural AMPs is hampered by systemic toxicity and high synthesis costs. This study introduces a novel strategy based on a quadruple repeating unit (A 1 A 2 B 1 B 2 ) n , employing tyrosine (Y) as a key hydrophobic residue to reduce overall hydrophobicity and hemolytic activity while maintaining antimicrobial efficacy. The candidate peptide (RRLY) 4 exhibited broad‐spectrum antimicrobial activity against reference strains (minimum inhibitory concentrations (MICs): 15.63–125 μg/mL), combined with low hemolytic activity (HC 50 > 1500 μg/mL) and a therapeutic index exceeding 31.66. Furthermore, (RRLY) 4 possessed potent antimicrobial effects against five clinically isolated MDR bacteria, with MICs ranging from 15.63 to 31.25 μg/mL, and also showed low salt sensitivity. Additionally, mechanism of action studies revealed that (RRLY) 4 exerted rapid bactericidal activity by disrupting the membrane integrity of Staphylococcus aureus ATCC 25 923 and Escherichia coli ATCC 25 922. This study demonstrates that tyrosine can serve as a hydrophobic residue in the rational design of AMPs, offers a strategy for developing amphipathic AMPs with potent antimicrobial activity and low hemolytic activity.
No takes yet. Share an insight, caveat, or question.
Na et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: